Cas:953721-14-7 3-(3-bromoindol-1-yl)propanoic acid manufacturer & supplier

Chemical Name:3-(3-bromoindol-1-yl)propanoic acid

CAS.NO:953721-14-7

Synonyms:1H-Indole-1-propanoicacid,3-bromo

Molecular Formula:C₁₁H₁₀BrNO₂

Molecular Weight:268.10700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:42.23000

Exact Mass:266.98900

LogP:2.87850

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1H-Indole-1-propanoicacid,3-bromo chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1H-Indole-1-propanoicacid,3-bromo physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1H-Indole-1-propanoicacid,3-bromo Use and application,1H-Indole-1-propanoicacid,3-bromo technical grade,usp/ep/jp grade.

Related News: The purpose of APIs according to the FDA is to cause ��pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body. 3-(3-bromoindol-1-yl)propanoic acid manufacturer The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. 3-(3-bromoindol-1-yl)propanoic acid supplier The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. 3-(3-bromoindol-1-yl)propanoic acid vendor The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. 3-(3-bromoindol-1-yl)propanoic acid factory This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved.